ANDAORALCAPSULE
Approved
Aug 2006
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TRIMIPRAMINE MALEATE (trimipramine maleate) by Teva is clinical pharmacology trimipramine capsules are an antidepressant with an anxiety-reducing sedative component to its action. First approved in 2006.
Drug data last refreshed 1w ago
Mechanism of Action
CLINICAL PHARMACOLOGY Trimipramine capsules are an antidepressant with an anxiety-reducing sedative component to its action. The mode of action of trimipramine capsules on the central nervous system is not known. However, unlike amphetamine-type compounds it does not act primarily by stimulation of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Worked on TRIMIPRAMINE MALEATE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.